Efficacy of tulathromycin injectable solution for the treatment of naturally occurring swine respiratory disease

Veterinary Therapeutics

Volumn 6, Issue 2, 2005, Pages 214-224

  Nutsch, Robert G ^a   Hart, Fred J ^a   Rooney, Kathleen A ^a   Weigel, Daniel J ^a   Kilgore, W Randal ^a   Skogerboe, Terry L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFTIOFUR; CEPHALOSPORIN DERIVATIVE; DISACCHARIDE; HETEROCYCLIC COMPOUND; TULATHROMYCIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; CATTLE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRAM NEGATIVE BACTERIUM; HOSPITALIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTICENTER STUDY; MYCOPLASMA HYOPNEUMONIAE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SWINE; SWINE DISEASE; TREATMENT OUTCOME; UNITED STATES;

ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DISACCHARIDES; FEMALE; GRAM-NEGATIVE BACTERIA; HETEROCYCLIC COMPOUNDS; INJECTIONS, INTRAMUSCULAR; MALE; MICROBIAL SENSITIVITY TESTS; MYCOPLASMA HYOPNEUMONIAE; PASTEURELLOSIS, PNEUMONIC; SEVERITY OF ILLNESS INDEX; SWINE; SWINE DISEASES; TREATMENT OUTCOME; UNITED STATES;

ACTINOBACILLUS PLEUROPNEUMONIAE; HAEMOPHILUS PARASUIS; MYCOPLASMA HYOPNEUMONIAE; PASTEURELLA MULTOCIDA; SUS SCROFA;

EID: 24044496600     PISSN: 15283593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Amass SF, Clark LK, Van Alstine WG, et al: Interaction of Mycoplasma hyopneumoniae and Pasteurella multocida infections in swine. JAVMA 204:102-107, 1994.
2. Veenhuizen MF: Three bacterial pathogens in the porcine respiratory complex. Compend Contin Educ Pract Vet 20:S11-S21, 1998.
3. Choi YK, Goyal SM, Joo HS: Retrospective analysis of etiologic agents associated with respiratory diseases in pigs. Can Vet J 444:734-737, 2003.
4. Derossiers R: A review of some aspects of the epidemiology, diagnosis, and control of Mycoplasma hyopneumoniae infections. J Swine Health Pro 9:233-237, 2001.
5. Straw B, Duran O: Causal factors in swine pneumonia, in Howard JL, Smith RA (eds): Current Veterinary Therapy 4: Food Animal Practice. Philadelphia, WB Saunders, 1994, pp 437-443.
6. MacInnes JI, Paradis MA, Vessie GH, et al: Efficacy of prophylactic tilmicosin in the control of experimentally induced Haemophilus parasuis infections in pigs. J Swine Health Prod 11(4):174-180, 2003.
7. Fenwick B, Henry S: Porcine pleuropneumonia. JAVMA 204:1334-1340, 1994.
8. Fenwick B, Henry S: Porcine contagious pleuropneumonia, in Howard JL, Smith RA (eds): Current Veterinary Therapy 4: Food Animal Practice. Philadelphia, WB Saunders, 1994, pp 361-364.
9. Diarra MS, Malouin F, Jacques M: Postantibiotic and physiological effects of tilmicosin, tylosin and apramycin at subminimal and suprainhibitory concentrations on some swine and bovine respiratory tract pathogens. Int J Antimicrob Agents 12:229-237, 1999.
10. Hoflack G, Maes D, Mateusen B, et al: Efficacy of tilmicosin phosphate (Pulmotil premix) in feed for the treatment of a clinical outbreak of Actinobacillus pleuropneumoniae infection in growing-finishing pigs. J Vet Med B Infect Dis Vet Public Health 48:655-664, 2001.
11. Moore GM, Basson R, Tonkinson LV: Clinical field trials with tilmicosin phosphate in feed for the control of naturally acquired pneumoniae caused by Actinobacillus pleuropneumoniae and Pasteurella multocida in swine. Am J Vet Res 57:223-224, 1996.
12. Inamoto T, Dikuchi K, Iijima H, et al: Antibacterial activity of tilmicosin against Pasteurella multocida and Actinobacillus pleuropneumoniae isolated from pneumonic lesions in swine. J Vet Med Sci 56:917-921, 1994.
13. Inamoto T, Takahashi H, Yamamoto K, et al: Antibiotic susceptibility of Mycoplasma hyopneumoniae isolated from swine. J Vet Med Sci 56:393-394, 1994.
14. Thacker EL, Young TF, Erickson BZ, DeBey MC: Evaluation of the ability of tilmicosin to prevent adherence of Mycoplasma hyopneumoniae to cilia using a differentiated swine respiratory epithelial culture system. Vet Ther 2:96-103, 2001.
15. Nightengale CH: Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J 16:438-443, 1997.
16. Patel KB, Xuan D, Tessier PR, et al: Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 40:2375-2379, 1996.
17. Scorneaux B, Shryock TR: Intracellular accumulation, subcellular distribution and efflux of tilmicosin in swine phagocytes. J Vet Pharmacol Ther 21:257-268, 1998.
18. Carbon C: Pharmacodynamics of macrolides, azalides, and streptogramins: Effect on extracellular pathogens. Clin Infect Dis 27:28-32, 1998.
19. Gladue RP, Bright GM, Isaacson RE, Newborg MF: In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 33:277-282, 1989.
20. Rothermel CD: Single dose azithromycin for acute otitis media: A pharmacokinetic/pharmacodynamic rationale. Curr Ther Res Clin Exp 64(suppl A):A4-A15, 2003.
21. Letavic MA, Bronk BS, Bertsche CD, et al: Synthesis and activity of a novel class of tribasic macrocyclic antibiotics: The triamilides. Bioorg Med Chem Lett 12:2771-2774, 2002.
22. Bright GM, Nagel AA, Bordner J, et al: Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides. J Antibiot 41:1029-1047, 1988.
23. Benchaoui HA, McLean C, Williams S, et al: Pharmacokinetics and lung tissue concentrations of tulathromycin in swine. J Vet Pharmacol Ther 27:203-210, 2004.
24. Siegel TW, Earley DL, Smothers CD, et al: Cellular uptake of the triamilide tulathromycin by bovine and porcine phagocytic cells in vitro. J Anim Sci 82:S186, 2004.
25. Norcia LJL, Silvia AM, Santoro SL, et al: In vitro microbiological characterization of a novel azalide, two triamilides and an azalide ketal against bovine and porcine respiratory pathogens. J Antibiot 57:280-288, 2004.
26. Guidance for Industry #58: Good Target Animal Study Practices: Clinical Investigators and Monitors. Rockville, MD, FDA/CVM, May 1997.
27. Federation of Animal Science Societies (FASS): Guide for the Care and Use of Agricultural Animals in Agriculture Research and Teaching, ed 1 rev. Savoy, IL, FASS, 1999.
28. National Committee for Clinical Laboratory Standards (NCCLS; now Clinical and Laboratory Standards Institute [CLSI]): Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals [approved standard]. NCCLS Doc. M31-A. NCCLS, 1999.
29. Wu CC, Shyrock TR, Lin TL, Veenhuizen MF: Testing antimicrobial susceptibility against Mycoplasma hyopneumoniae in vitro. J Swine Health Prod (6):227-230, 1997.
30. 2 and serum) on MIC values of tulathromycin against Haemophilus somnus [abstract 532]. Proc 23rd World Buiatrics Congr:70-71, 2004.
31. 2. J Antimicrob Chemother 41:387-389, 1998.
32. Godinho KS, Keane SG, Nanjiani IA, et al: Minimum inhibitory concentrations of tulathromycin against respiratory bacterial pathogens isolated from clinical cases in European cattle and swine and variability arising from changes in in vitro methodology. Vet Ther 6(2):113-121, 2005.
33. Hart FJ, Kilgore RW, Lechtenberg KF, et al: Efficacy of a single parenteral dose of tulathromycin versus three doses of ceftiofur to treat experimental swine respiratory disease caused by Actinobacillus pleuropneumoniae. Vet Rec, in press, 2005.